Zai Lab promotes Harald Reinhart to President and Head of Global Development

Zai Lab Ltd

Harald Reinhart, M.D., promoted from CMO to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Reinhart received a special equity grant of 30,000 restricted share units, with 50% vesting immediately and 50% on Dec 31, 2022
Base salary and target bonus for 2022 and 2021 bonus increased to be commensurate with other executive officers
Reinhart has been with Zai Lab since inception, first as advisor and since 2017 as CMO
Prior to Zai Lab, he served at Shionogi U.S., Novartis, and Bayer Corp with broad clinical development experience

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Harald Reinhart

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases

ZLAB · Zai Lab Ltd

Effective: 2021-12-21
Filed: December 22, 2021, 6:59 PM ET

On December 22, 2021, Zai Lab Limited (the “Company”) announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Harald Reinhart changed role as President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Ltd.

Action: promoted
Role: President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases

Exact text from the filing

On December 22, 2021, Zai Lab Limited (the “Company”) announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases.

View on SEC.gov

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001193125-21-364991

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.